ArticleEBioMedicine2026
Blood DNA methylation and breast cancer risk: a prospective nested case-control study.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBlood tests that predict breast cancer (BC) risk before diagnosis could complement mammography screening. Whole-blood DNA methylation is stable and may capture early systemic changes related to tumour development.
methodsWe conducted a prospective matched case-control study nested within Sweden's mammography screening programme, profiling whole-blood DNA methylation on the Illumina MethylationEPIC array in 377 female participants who later developed BC and 378 age-matched female controls. We identified methylation sites (CpG sites) in Stockholm and validated them in Skåne, after stringent quality control and adjustment for technical and epidemiological confounders. We then constructed a methylation risk score (MRS).
findingsWe identified 87 CpG sites in Stockholm (FDR < 0.05; |β| > 0.015), of which 22 validated in Skåne (P < 0.05; concordant direction) and formed the MRS. The MRS demonstrated significant associations with BC risk, was consistent across different BC subtypes, and independent of established risk factors. The association of MRS with BC remained relatively stable over a pre-diagnostic window of up to five years. MRS exhibited predictive performance comparable to a polygenic risk score, and it significantly improved the 3-5-year prediagnosis discrimination of established BC risk models (P < 0.05, DeLong's test). Several CpG sites correlated with immune-related genes, suggesting mechanisms involving immune modulation and tumour progression.
interpretationOur methylation signature was significantly associated with BC risk and may complement existing risk models, particularly for estimating 3-5-year risk. These findings suggest that blood DNA methylation may support BC risk stratification, although further validation and assessment of clinical utility are needed.
fundingSwedish Research Council; Swedish Cancer Society; Stockholm County Council; Cancerföreningen i Stockholm; Erling-Persson Foundation; Sjöberg Foundation; and EU funds via ILB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.